Tags

Type your tag names separated by a space and hit enter

Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19.
Stem Cells Transl Med. 2020 10; 9(10):1163-1173.SC

Abstract

The broad immunomodulatory properties of human mesenchymal stem cells (MSCs) have allowed for wide application in regenerative medicine as well as immune/inflammatory diseases, including unmatched allogeneic use. The novel coronavirus disease COVID-19 has unleashed a pandemic in record time accompanied by an alarming mortality rate mainly due to pulmonary injury and acute respiratory distress syndrome. Because there are no effective preventive or curative therapies currently, MSC therapy (MSCT) has emerged as a possible candidate despite the lack of preclinical data of MSCs for COVID-19. Interestingly, MSCT preclinical data specifically on immune/inflammatory disorders of the lungs were among the earliest to be reported in 2003, with the first clinical use of MSCT for graft-vs-host disease reported in 2004. Since these first reports, preclinical data showing beneficial effects of MSC immunomodulation have accumulated substantially, and as a consequence, over a third of MSCT clinical trials now target immune/inflammatory diseases. There is much preclinical evidence for MSCT in noninfectious-including chronic obstructive pulmonary disease, asthma, and idiopathic pulmonary fibrosis-as well as infectious bacterial immune/inflammatory lung disorders, with data generally demonstrating therapeutic effects; however, for infectious viral pulmonary conditions, the preclinical evidence is more scarce with some inconsistent outcomes. In this article, we review the mechanistic evidence for clinical use of MSCs in pulmonary immune/inflammatory disorders, and survey the ongoing clinical trials-including for COVID-19-of MSCT for these diseases, with some perspectives and comment on MSCT for COVID-19.

Authors+Show Affiliations

Regenerative Medicine Research Group, Institute of Cellular & System Medicine, National Health Research Institutes (NHRI), Zhunan, Taiwan.Department of Obstetrics/Gynecology, National Taiwan University (NTU) Hospital & College of Medicine, NTU, Taipei, Taiwan.Department of Obstetrics/Gynecology, National Taiwan University (NTU) Hospital & College of Medicine, NTU, Taipei, Taiwan.National Institute of Cancer Research, NHRI, Tainan, Taiwan.National Institute of Infectious Diseases & Vaccinology, NHRI, Zhunan, Taiwan. Department & Graduate Institute of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32526079

Citation

Yen, B Linju, et al. "Current Status of Mesenchymal Stem Cell Therapy for Immune/inflammatory Lung Disorders: Gleaning Insights for Possible Use in COVID-19." Stem Cells Translational Medicine, vol. 9, no. 10, 2020, pp. 1163-1173.
Yen BL, Yen ML, Wang LT, et al. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19. Stem Cells Transl Med. 2020;9(10):1163-1173.
Yen, B. L., Yen, M. L., Wang, L. T., Liu, K. J., & Sytwu, H. K. (2020). Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19. Stem Cells Translational Medicine, 9(10), 1163-1173. https://doi.org/10.1002/sctm.20-0186
Yen BL, et al. Current Status of Mesenchymal Stem Cell Therapy for Immune/inflammatory Lung Disorders: Gleaning Insights for Possible Use in COVID-19. Stem Cells Transl Med. 2020;9(10):1163-1173. PubMed PMID: 32526079.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19. AU - Yen,B Linju, AU - Yen,Men-Luh, AU - Wang,Li-Tzu, AU - Liu,Ko-Jiunn, AU - Sytwu,Huey-Kang, Y1 - 2020/06/11/ PY - 2020/04/29/received PY - 2020/05/18/revised PY - 2020/05/24/accepted PY - 2020/6/12/pubmed PY - 2020/12/22/medline PY - 2020/6/12/entrez KW - ARDS KW - COPD KW - COVID-19 KW - asthma KW - bacterial pneumonia KW - clinical trial KW - cytokine storm KW - idiopathic pulmonary fibrosis KW - influenza KW - mesenchymal stem cells SP - 1163 EP - 1173 JF - Stem cells translational medicine JO - Stem Cells Transl Med VL - 9 IS - 10 N2 - The broad immunomodulatory properties of human mesenchymal stem cells (MSCs) have allowed for wide application in regenerative medicine as well as immune/inflammatory diseases, including unmatched allogeneic use. The novel coronavirus disease COVID-19 has unleashed a pandemic in record time accompanied by an alarming mortality rate mainly due to pulmonary injury and acute respiratory distress syndrome. Because there are no effective preventive or curative therapies currently, MSC therapy (MSCT) has emerged as a possible candidate despite the lack of preclinical data of MSCs for COVID-19. Interestingly, MSCT preclinical data specifically on immune/inflammatory disorders of the lungs were among the earliest to be reported in 2003, with the first clinical use of MSCT for graft-vs-host disease reported in 2004. Since these first reports, preclinical data showing beneficial effects of MSC immunomodulation have accumulated substantially, and as a consequence, over a third of MSCT clinical trials now target immune/inflammatory diseases. There is much preclinical evidence for MSCT in noninfectious-including chronic obstructive pulmonary disease, asthma, and idiopathic pulmonary fibrosis-as well as infectious bacterial immune/inflammatory lung disorders, with data generally demonstrating therapeutic effects; however, for infectious viral pulmonary conditions, the preclinical evidence is more scarce with some inconsistent outcomes. In this article, we review the mechanistic evidence for clinical use of MSCs in pulmonary immune/inflammatory disorders, and survey the ongoing clinical trials-including for COVID-19-of MSCT for these diseases, with some perspectives and comment on MSCT for COVID-19. SN - 2157-6580 UR - https://www.unboundmedicine.com/medline/citation/32526079/Current_status_of_mesenchymal_stem_cell_therapy_for_immune/inflammatory_lung_disorders:_Gleaning_insights_for_possible_use_in_COVID_19_ DB - PRIME DP - Unbound Medicine ER -